Results For "Bosutinib-tablets"

2 News Found

Alembic announces USFDA tentative approval for Bosutinib tablets

Drug Approval | January 12, 2026

Alembic announces USFDA tentative approval for Bosutinib tablets

Alembic announces USFDA tentative approval for Bosutinib Tablets, 100 mg and 500 mg

Drug Approval | July 02, 2024

Alembic announces USFDA tentative approval for Bosutinib Tablets, 100 mg and 500 mg

Latest Stories

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients

PsiQuantum joins forces with Japan’s National Cancer Center to revolutionize cancer research with quantum computing

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging